Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function
about
Emerging Vaccine TechnologiesThe use of humanized monoclonal antibodies for the prevention of respiratory syncytial virus infectionVaccination with human papillomavirus pseudovirus-encapsidated plasmids targeted to skin using microneedlesStructural basis of respiratory syncytial virus neutralization by motavizumabStructure of a Major Antigenic Site on the Respiratory Syncytial Virus Fusion Glycoprotein in Complex with Neutralizing Antibody 101FDesign and Characterization of Epitope-Scaffold Immunogens That Present the Motavizumab Epitope from Respiratory Syncytial VirusStructural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titersStructure of Respiratory Syncytial Virus Fusion Glycoprotein in the Postfusion Conformation Reveals Preservation of Neutralizing EpitopesStructure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing AntibodyDiscovery and Characterization of Phage Display-Derived Human Monoclonal Antibodies against RSV F GlycoproteinLlama-derived single domain antibodies to build multivalent, superpotent and broadened neutralizing anti-viral moleculesRespiratory Syncytial Virus: Infection, Detection, and New Options for Prevention and Treatment.Novel insights into human respiratory syncytial virus-host factor interactions through integrated proteomics and transcriptomics analysisEfficient generation of respiratory syncytial virus (RSV)-neutralizing human MoAbs via human peripheral blood lymphocyte (hu-PBL)-SCID mice and scFv phage display libraries.Human monoclonal Fab fragments derived from a combinatorial library bind to respiratory syncytial virus F glycoprotein and neutralize infectivity.Human antibody responses to mature and immature forms of viral envelope in respiratory syncytial virus infection: significance for subunit vaccines.Intranasal antibody prophylaxis for protection against viral disease.Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3.Modification of the respiratory syncytial virus f protein in virus-like particles impacts generation of B cell memory.New insights for development of a safe and protective RSV vaccineHyperimmune globulins in prevention and treatment of respiratory syncytial virus infections.Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backboneNeutralizing anti-F glycoprotein and anti-substance P antibody treatment effectively reduces infection and inflammation associated with respiratory syncytial virus infection.Recombinant respiratory syncytial virus with the G and F genes shifted to the promoter-proximal positionsPhage display-based strategies for cloning and optimization of monoclonal antibodies directed against human pathogensBiological challenges and technological opportunities for respiratory syncytial virus vaccine development.Respiratory syncytial virus fusion glycoprotein expressed in insect cells form protein nanoparticles that induce protective immunity in cotton ratsAnalysis of respiratory syncytial virus preclinical and clinical variants resistant to neutralization by monoclonal antibodies palivizumab and/or motavizumabA protective and safe intranasal RSV vaccine based on a recombinant prefusion-like form of the F protein bound to bacterium-like particles.Soluble respiratory syncytial virus fusion protein in the fully cleaved, pretriggered state is triggered by exposure to low-molarity buffer.In vitro and in vivo fitness of respiratory syncytial virus monoclonal antibody escape mutants.Palivizumab epitope-displaying virus-like particles protect rodents from RSV challenge.Future opportunities for passive immunity against viral diseases.Progress in understanding and controlling respiratory syncytial virus: still crazy after all these yearsCharacterization of a Prefusion-Specific Antibody That Recognizes a Quaternary, Cleavage-Dependent Epitope on the RSV Fusion GlycoproteinSerious Adverse Events in the Canadian Registry of Children Receiving Palivizumab (CARESS) for Respiratory Syncytial Virus PreventionMurine immune responses to virus-like particle-associated pre- and postfusion forms of the respiratory syncytial virus F proteinFrequent frameshift and point mutations in the SH gene of human metapneumovirus passaged in vitro.An anti-G protein monoclonal antibody treats RSV disease more effectively than an anti-F monoclonal antibody in BALB/c mice.Evaluation of pneumonia virus of mice as a possible human pathogen
P2860
Q26783764-81A6DB34-9671-4436-9168-B3C9DDDCD7BFQ26864494-02E55911-ECC7-4F30-9EE0-9D49D9AA2CA9Q27311290-39749CBF-BCA6-4ACF-B512-A1334EC8B30AQ27659146-2C696B27-AA0B-4E0E-8A1F-EB3F4EFF96C5Q27664797-6113CCA5-4E44-4600-942D-79C39D04EDDDQ27667750-BC181B84-274C-48B2-8DC6-DE2B7C64C4E0Q27667876-0990B666-EFF2-463B-9F34-19703207D357Q27668015-7AF1D50F-BEC6-44A2-AB17-4003A30F0706Q27677570-E660976F-22AB-41B8-82E3-F3A1948F6D9AQ28552644-4D91443D-45DD-4D37-A85C-305845D893DAQ28741431-8974C1C4-B3ED-492E-A810-F17A29B2DE46Q30240274-3BA0BD07-AE97-437F-BA09-32A4097531E8Q30385012-037D18BD-A6D2-4BBD-ABE8-D4A9EC90A1DEQ30933288-B5366078-D584-4BCE-8B08-8E131296AA6CQ30946151-DB519E81-DDBB-4890-A784-11D8F3456D02Q33177627-B81F6C8A-EC49-48CB-A917-09A4E2AFAEF9Q33683058-4A5F2833-71E2-4020-8B7C-725034359FF7Q33840469-06B88D95-6E49-44A6-964A-15E08A128F00Q34059404-0893A1C5-44CC-448B-BA79-F19D3E82F001Q34249859-1AF5512C-86CA-40AF-91E3-3A53FF8B4D80Q34307704-397B1E02-B172-42A3-A65C-0C66E25E6647Q34328895-F5824CAE-0D1D-4407-A215-2123265C4DF1Q34341948-E43F390F-2F9E-4600-8D59-E220F5D5459BQ34359826-64D7C949-7DC7-488C-9FAA-D70A79A64ACDQ34401573-1A824832-5FDB-4B30-8E20-7CC30DE5235BQ34504791-E6D0A9D8-C018-4C7E-892F-D7167DF686EEQ34506016-F6F5DAFF-B37E-42B3-96CB-E03BDF89E71EQ34772752-F525A111-B88B-4521-B8DC-CAB5E92EC3B5Q34948645-E438F3D8-AECC-4AB1-90E0-935BBA35C79CQ35076596-42B6FC70-C39A-49C5-83AE-7E58F776EF5BQ35140093-F7C2FC00-2760-42E6-9A70-3B93605E110CQ35535626-C67EA06B-E595-4822-AE12-F25BABC1CB2CQ35557110-025E4477-41BC-4DCD-8FB3-6CD0639ACDB7Q35566601-87A8D87F-787B-4F2B-B28F-EFDD8D195C08Q35687662-876CAA64-1C4A-4CB7-A5B3-2B604C41532BQ35735115-482655D2-C632-4243-879C-27C1346AFBCEQ35745343-97720E48-C099-488D-BF98-2F26085041D3Q35857720-DD482A96-26A0-424B-A89E-51F78FDBC957Q35893983-C2C972F6-FC97-465C-B1FE-7149BA43D1BFQ35943578-9B535DED-F7EF-41B5-B85F-8DD5B9E3EA2A
P2860
Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function
description
1989 nî lūn-bûn
@nan
1989 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1989 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
name
Neutralization epitopes of the ...... mutation upon fusion function
@ast
Neutralization epitopes of the ...... mutation upon fusion function
@en
Neutralization epitopes of the ...... mutation upon fusion function
@nl
type
label
Neutralization epitopes of the ...... mutation upon fusion function
@ast
Neutralization epitopes of the ...... mutation upon fusion function
@en
Neutralization epitopes of the ...... mutation upon fusion function
@nl
prefLabel
Neutralization epitopes of the ...... mutation upon fusion function
@ast
Neutralization epitopes of the ...... mutation upon fusion function
@en
Neutralization epitopes of the ...... mutation upon fusion function
@nl
P2860
P3181
P1433
P1476
Neutralization epitopes of the ...... mutation upon fusion function
@en
P2093
J A Beeler
K van Wyke Coelingh
P2860
P304
P3181
P577
1989-07-01T00:00:00Z